Delhi High Court Records Sun Pharma’s Assurance Not to Sell Semaglutide in India Until 2026

The Delhi High Court recorded Sun Pharmaceutical’s undertaking that it will not sell its semaglutide-based drug in India until March 20, 2026, when Novo Nordisk’s patent expires.

The Court allowed Sun Pharma to export the drug only to countries where Novo does not hold patent rights.

This development follows similar commitments recently given by Dr. Reddy’s Laboratories and OneSource Specialty Pharma in related semaglutide litigation.

The Court directed Sun Pharma to file an affidavit confirming its undertaking and to disclose details of its export accounts.

The company said it may rely on findings in the earlier December 2 order if appealed. 

[Novo Nordisk & Anr v. Sun Pharmaceutical Industries Ltd]